O. V. Polyakova
O. V. Polyakova has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Bogdan Tsubera
O. O. Shalimov National Scientific Center for Surgery and Transplantology, Kyiv
2 shared publications - M. V. Antonenko
O. O. Shalimov National Scientific Center for Surgery and Transplantology, Kyiv
2 shared publications - O. M. Simonov
Державна установа «Національний науковий центр хірургії та трансплантології імені О. О. Шалімова» Національної академії медичних наук України, Київ, Україна
2 shared publications - P. V. Hurin
National Scientific Center for Surgery and Transplantology named after O.O. Shalimov of NAMSU, Kyiv, Ukraine
2 shared publications - A. A. Skums
Shalimov National Scientific Center of Surgery and Transplantation
1 shared publication - O. M. Gulko
Національний інститут хірургії та трансплантології імені О. О. Шалімова НАМН України, м. Київ
1 shared publication
Latest Publications
- Open Access
- 23 February 2026
- Published by Liga-Inform, Ltd. in The Ukrainian Journal of Clinical Surgery
- Vol. 93 (1) , 69-73
Genotype-phenotype correlations and clinical significance of genetic testing in pheochromocytomas and paragangliomas
Objective. To evaluate the role of molecular genetic testing in patients with pheochromocytomas and paragangliomas, to determine genotype-phenotype correlations and their impact on clinical characteristics, imaging approaches, and prognosis. Materials and methods. The prospective study included 14 patients hospitalized at the O. O. Shalimov National Scientific Center for Surgery and Transplantology of the National Academy of Medical Sciences of Ukraine in 2018–2025. All patients underwent genetic testing using next-generation sequencing with confirmation of mutations by the Sanger method, biochemical examination (liquid chromatography–tandem mass spectrometry for metanephrines, normetanephrines, 3-methoxytyramine), morphological and immunohistochemical studies. Computed tomography and magnetic resonance imaging were performed, as well as functional imaging (positron emission tomography/computed tomography using the radiopharmaceuticals DOTA-SSA and FDOPA). Descriptive and comparative statistics were used for statistical analysis. Results. Pathogenic or likely pathogenic gene mutations were detected in 12 (85.7%) of 14 patients. The most common were SDHB gene mutations (64.3%), associated with a noradrenergic or "biochemically silent" phenotype and a high risk of metastasis (21.4%). Patients with VHL and RET (MEN2A) gene mutations had characteristic multifocality and bilateral tumors. Functional imaging revealed genotype-specific patterns: positron emission tomography/computed tomography with DOTA-SSA demonstrated high sensitivity in SDHB-associated tumors (over 90%), while FDOPA was optimal for VHL- and RET/NF1-associated tumors. The disease debuted earliest in patients with SDHB-associated tumors (median age 32 years), and its clinical manifestations differed depending on the genotype. Conclusions. Molecular genetic testing is critically important for risk stratification and personalized management of patients with pheochromocytomas/paragangliomas. Identification of genotype-phenotype correlations enables disease prognosis, informed choice of functional imaging method, planning of screening for first-degree relatives , and determination of therapeutic strategy, including theranostic approaches.
- 23 February 2026
- Published by Liga-Inform, Ltd. in The Ukrainian Journal of Clinical Surgery
- Vol. 93 (1) , 69-73
Open AccessGenotype-phenotype correlations and clinical significance of genetic testing in pheochromocytomas and paragangliomas
Objective. To evaluate the role of molecular genetic testing in patients with pheochromocytomas and paragangliomas, to determine genotype-phenotype correlations and their impact on clinical characteristics, imaging approaches, and prognosis. Materials and methods. The prospective study included 14 patients hospitalized at the O. O. Shalimov National Scientific Center for Surgery and Transplantology of the National Academy of Medical Sciences of Ukraine in 2018–2025. All patients underwent genetic testing using next-generation sequencing with confirmation of mutations by the Sanger method, biochemical examination (liquid chromatography–tandem mass spectrometry for metanephrines, normetanephrines, 3-methoxytyramine), morphological and immunohistochemical studies. Computed tomography and magnetic resonance imaging were performed, as well as functional imaging (positron emission tomography/computed tomography using the radiopharmaceuticals DOTA-SSA and FDOPA). Descriptive and comparative statistics were used for statistical analysis. Results. Pathogenic or likely pathogenic gene mutations were detected in 12 (85.7%) of 14 patients. The most common were SDHB gene mutations (64.3%), associated with a noradrenergic or "biochemically silent" phenotype and a high risk of metastasis (21.4%). Patients with VHL and RET (MEN2A) gene mutations had characteristic multifocality and bilateral tumors. Functional imaging revealed genotype-specific patterns: positron emission tomography/computed tomography with DOTA-SSA demonstrated high sensitivity in SDHB-associated tumors (over 90%), while FDOPA was optimal for VHL- and RET/NF1-associated tumors. The disease debuted earliest in patients with SDHB-associated tumors (median age 32 years), and its clinical manifestations differed depending on the genotype. Conclusions. Molecular genetic testing is critically important for risk stratification and personalized management of patients with pheochromocytomas/paragangliomas. Identification of genotype-phenotype correlations enables disease prognosis, informed choice of functional imaging method, planning of screening for first-degree relatives , and determination of therapeutic strategy, including theranostic approaches.
- Open Access
- 24 October 2025
- Published by Liga-Inform, Ltd. in The Ukrainian Journal of Clinical Surgery
- Vol. 92 (5) , 50-59
Comprehensive personalized approach to the diagnosis and treatment of pheochromocytoma and paraganglioma
Objective. To evaluate the effectiveness of a comprehensive approach to the diagnosis and treatment of pheochromocytoma and paraganglioma with a special focus on the role of selective venous blood sampling, X–ray endovascular selective electrocoagulation occlusion, and biochemical stratification in optimizing surgical tactics in domestic clinical practice. Materials and methods. The study included 248 patients with morphologically confirmed pheochromocytomas and paragangliomas who were treated at the O. O. Shalimov National Scientific Center for Surgery and Transplantology in 2016–2025: 129 (52.0%) women and 119 (48.0%) men, with an average age of 47.0 (± 10.0) years. Shalimov National Scientific Center for Surgery and Transplantology in 2016–2025: 129 (52.0%) women and 119 (48.0%) men, with a mean age of (43.8 ± 12.4) years. All patients underwent blood plasma metanephrine level determination using high–performance liquid chromatography with tandem mass spectrometry, as well as computed tomography and magnetic resonance imaging. Selective venous blood sampling was performed in 35 patients with complex diagnoses, and selective endovascular electrocoagulation occlusion was performed in 183 patients as part of preoperative preparation. Next–generation sequencing genetic testing was performed in 12 patients. All patients underwent surgery after adequate α–blockade. Results. Elevated metanephrine levels were detected in 91.9% of patients. In 75% of patients with "biochemically silent" tumors, the diagnosis was established by determining the level of 3–methoxytyramine. Selective venous blood sampling allowed lateralization in 80% of patients and changed surgical tactics in 31.4% of patients, avoiding bilateral adrenalectomy in 5 patients. X–ray endovascular selective electrocoagulation occlusion led to normalization of metanephrine levels in 66.7% and ensured hemodynamic stability during surgery in 91.8% of patients. The average blood loss after this procedure was (66.4 ± 12.2) ml. Mutations in genes were detected in 83.3% of patients, mainly in the SDHB gene (90%). The overall incidence of postoperative complications was 8.9%, and the three–year recurrence–free survival rate was 92.1%. Conclusions. A comprehensive approach using selective venous blood sampling and X–ray endovascular selective electrocoagulation occlusion significantly improves the results of treatment for pheochromocytoma and paraganglioma. Selective venous blood sampling allows optimizing surgical tactics and avoiding unnecessary bilateral adrenalectomies. X–ray endovascular selective electrocoagulation occlusion effectively reduces hormonal load and intraoperative risks. Determination of 3–methoxytyramine levels increases diagnostic sensitivity in patients with "biochemically silent" tumors. Genetic testing is critical for predicting the course of the disease.
- 24 October 2025
- Published by Liga-Inform, Ltd. in The Ukrainian Journal of Clinical Surgery
- Vol. 92 (5) , 50-59
Open AccessComprehensive personalized approach to the diagnosis and treatment of pheochromocytoma and paraganglioma
Objective. To evaluate the effectiveness of a comprehensive approach to the diagnosis and treatment of pheochromocytoma and paraganglioma with a special focus on the role of selective venous blood sampling, X–ray endovascular selective electrocoagulation occlusion, and biochemical stratification in optimizing surgical tactics in domestic clinical practice. Materials and methods. The study included 248 patients with morphologically confirmed pheochromocytomas and paragangliomas who were treated at the O. O. Shalimov National Scientific Center for Surgery and Transplantology in 2016–2025: 129 (52.0%) women and 119 (48.0%) men, with an average age of 47.0 (± 10.0) years. Shalimov National Scientific Center for Surgery and Transplantology in 2016–2025: 129 (52.0%) women and 119 (48.0%) men, with a mean age of (43.8 ± 12.4) years. All patients underwent blood plasma metanephrine level determination using high–performance liquid chromatography with tandem mass spectrometry, as well as computed tomography and magnetic resonance imaging. Selective venous blood sampling was performed in 35 patients with complex diagnoses, and selective endovascular electrocoagulation occlusion was performed in 183 patients as part of preoperative preparation. Next–generation sequencing genetic testing was performed in 12 patients. All patients underwent surgery after adequate α–blockade. Results. Elevated metanephrine levels were detected in 91.9% of patients. In 75% of patients with "biochemically silent" tumors, the diagnosis was established by determining the level of 3–methoxytyramine. Selective venous blood sampling allowed lateralization in 80% of patients and changed surgical tactics in 31.4% of patients, avoiding bilateral adrenalectomy in 5 patients. X–ray endovascular selective electrocoagulation occlusion led to normalization of metanephrine levels in 66.7% and ensured hemodynamic stability during surgery in 91.8% of patients. The average blood loss after this procedure was (66.4 ± 12.2) ml. Mutations in genes were detected in 83.3% of patients, mainly in the SDHB gene (90%). The overall incidence of postoperative complications was 8.9%, and the three–year recurrence–free survival rate was 92.1%. Conclusions. A comprehensive approach using selective venous blood sampling and X–ray endovascular selective electrocoagulation occlusion significantly improves the results of treatment for pheochromocytoma and paraganglioma. Selective venous blood sampling allows optimizing surgical tactics and avoiding unnecessary bilateral adrenalectomies. X–ray endovascular selective electrocoagulation occlusion effectively reduces hormonal load and intraoperative risks. Determination of 3–methoxytyramine levels increases diagnostic sensitivity in patients with "biochemically silent" tumors. Genetic testing is critical for predicting the course of the disease.